Nicholas Turner, Professor of Molecular Oncology at the Institute of Cancer Research, is an gifted Medical Oncologist who has excelled in the research, development and application of cutting-edge molecular technology for breast cancer management. His major achievements fall into two categories – (i) CDK4/6 inhibition: his clinical trial of fulvestrant±palbociclib. He designed this on the basis of laboratory observations and led the investigator-initiated trial resulting in NICE approval of the combined treatment for advanced breast cancer in 2020. (ii) ctDNA: his advances in the early detection of recurrent disease and of targetable mutations in ctDNA acting as a liquid biopsy. These innovative advances are at the forefront of a revolution in the personalisation of breast cancer management.
Fellow
Back to directory listingProfessor Nicholas Turner FMedSci
Job Title
Professor of Molecular Oncology, The Institute of Cancer Research; ConsultantMedical Oncologist, Royal Marsden Hospital
Institution
The Institute of Cancer Research (ICR)
Year elected
2021
Interests
SpecialitiesMedical Oncology, breast cancer, clinical trial design, translational oncology and cancer drug development
Section committee elected bySurgery, anaesthesia, oncology, clinical pathologies, radiology, oral health, ophthalmology, reproductive health